Citius Pharmaceuticals Reaches 92 Event Milestone in Mino-Lok® Phase 3 Trial

CRANFORD, N.J., Aug. 10, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ('Citius' or the 'Company') (Nasdaq: CTXR), a late-stage biopharmaceuti...

Related Keywords

United States ,India ,Texas ,America ,Greg Salsburg ,Ilanit Allen ,Leonard Mazur ,Securities Exchange ,Citius Pharmaceuticals Inc ,Company Nasdaq ,Exchange Commission ,University Of Texas Md Anderson Cancer Center ,Infectious Diseases Society Of America ,Prnewswire Citius Pharmaceuticals Inc ,Chief Executive Officer ,Lok Phase ,Mino Lok Phase ,Infectious Diseases Society ,Citius Pharmaceuticals ,Fast Track ,Securities Act ,Securities Exchange Act ,Annual Report ,